Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit

Cancer Management and Research

Volumn 2, Issue 1, 2010, Pages 111-122

  Corn, Paul G ^a   Thompson, Timothy C ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Biomarker; Caveolin 1; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CAVEOLIN 1; GROWTH FACTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SCREENING; CARCINOGENESIS; CELL ADHESION; CELL FUNCTION; CELL MEMBRANE; CELL SURVIVAL; CELL TRANSPORT; CLINICAL FEATURE; CLINICAL TRIAL; CRYOSURGERY; IMMUNOASSAY; LYMPH NODE METASTASIS; NONHUMAN; PROSTATE CANCER; PROSTATECTOMY; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION;

EID: 77955347013     PISSN: None     EISSN: 11791322     Source Type: Book Series    
DOI: 10.2147/cmar.s9835     Document Type: Review

References (109)

1. Cher ML, Towler DA, Rafi S, et al. Cancer interaction with the bone microenvironment: A workshop of the National Institutes of Health Tumor Microenvironment Study Section. Am J Pathol. 2006;168: 1405-1412.
2. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer. 2005;5:21-28.
3. Rao AR, Motiwala HG, Karim OM. The discovery of prostate-specific antigen. BJU Int. 2008;101:5-10.
4. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268-278.
5. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302-6309.
6. Schiffer E. Biomarkers for prostate cancer. World J Urol. 2007;25: 557-562.
7. Reynolds MA. Molecular alterations in prostate cancer. Cancer Lett. 2008;271:13-24.
8. Masters JR. Clinical applications of expression profling and proteomics in prostate cancer. Anticancer Res. 2007;27:1273-1276.
9. Liszewski K. Optimizing Utilization of Biomarkers. Genetic Engineering and Biotechnology News. 28(12): Jun 15, 2009.
10. Corn PG. Methylation marks the path for biomarker development in breast cancer research. Cancer Biol Ther. 2009;8(23):2260-2262.
11. Thompson TC, Tahir SA, Li L, et al. Therole of caveolin-1 in prostate cancer: Clinical implications. Prostate Cancer Prostatic Dis. 2010;13(1):6-11.
12. Carver LA, Schnitzer JE. Caveolae: Mining little caves for new cancer targets. Nat Rev Cancer. 2003;3:571-581.
13. Tahir SA, Ren C, Timme TL, et al. Development of an immunoassay for serum caveolin-1: A novel biomarker for prostate cancer. Clin Cancer Res. 2003;9:3653-3659.
14. Tahir SA, Yang G, Goltsov AA, et al. Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res. 2008;68: 731-739.
15. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
16. Gann PH. Risk factors for prostate cancer. Rev Urol. 2002;4 Suppl 5: S3-S10.
17. Patel AR, Klein EA. Risk factors for prostate cancer. Nat Clin Pract Urol. 2009;6:87-95.
18. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: Final data for 2006. Natl Vital Stat Rep. 2009;57:1-134.
19. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625-1638.
20. Strom SS, Wang X, Pettaway CA, et al. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res. 2005;11:6889-6894.
21. Xu J, Gillanders EM, Isaacs SD, et al. Genome-wide scan for prostate cancer susceptibility genes in the Johns Hopkins hereditary prostate cancer families. Prostate. 2003;57:320-325.
22. Gayther SA, de Foy KA, Harrington P, et al. The frequency of germline mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Cancer Res. 2000;60:4513-4518.
23. Adolfsson J. Commentary: On the incidence of histological prostate cancer and the probable diagnosis of cases with tumours too small to produce symptoms or to attract attention on physical examination-the fndings of Dr. Arnold Rice Rich. Int J Epidemiol. 2007;36:285-287.
24. Winkler MH, Livni N, Mannion EM, Hrouda D, Christmas T. Characteristics of incidental prostatic adenocarcinoma in contemporary radical cystoprostatectomy specimens. BJU Int. 2007;99:554-558.
25. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA. 1997;277:467-471.
26. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291:2713-2719.
27. Bastian PJ, Carter BH, Bjartell A, et al. Insignifcant prostate cancer and active surveillance: From definition to clinical implications. Eur Urol. 2009;55:1321-1330.
28. Saitoh H, Hida M, Shimbo T, Nakamura K, Yamagata J, Satoh T. Metastatic patterns of prostatic cancer. Correlation between sites and number of organs involved. Cancer. 1984;54:3078-3084.
29. Scher HI, Heller G. Clinical states in prostate cancer: Toward a dynamic model of disease progression. Urology. 2000;55:323-327.
30. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148-1159.
31. Catalona WJ, Smith DS, Ratliff TL, Basler J W. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948-954.
32. Lu-Yao GL, Friedman M, Yao SL. Use of radical prostatectomy among Medicare beneficiaries before and after the introduction of prostate specific antigen testing. J Urol. 1997;157:2219-2222.
33. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
34. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003;21:2163-2172.
35. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977-1984.
36. Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-1319.
37. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
38. Autier P, Boniol M, Hery C, Masuyer E, Ferlay J. Cancer survival statistics should be viewed with caution. Lancet Oncol. 2007;8:1050-1052.
39. Aranha O, Vaishampayan U. PSA relapse prostate cancer: The importance of tailored therapy. Urol Oncol. 2004;22:62-69.
40. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term follow-up of a randomized clinical trial. J Urol. 2009;181:956-962.
41. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781-1788.
42. Pilepich M V, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285-1290.
43. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597.
44. Bhandari MS, Crook J, Hussain M. Should intermittent androgen deprivation be used in routine clinical practice? J Clin Oncol. 2005;23:8212-8218.
45. Crawford ED. Hormonal therapy in prostate cancer: Historical approaches. Rev Urol. 2004;6 Suppl 7:S3-S11.
46. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34-45.
47. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23:8253-8261.
48. Van Allen EM, Ryan CJ. Novel secondary hormonal therapy in advanced prostate cancer: An update. Curr Opin Urol. 2009;19:315-321.
49. Tannock I F, de WR, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
50. Petrylak D P, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
51. Manne U, Srivastava RG, Srivastava S. Recent advances in biomarkers for cancer diagnosis and treatment. Drug Discov Today. 2005;10:965-976.
52. Sawyers CL. The cancer biomarker problem. Nature. 2008;452: 548-552.
53. Balk S P, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol. 2003;21:383-391.
54. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909-916.
55. Partin AW, Kattan M W, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277:1445-1451.
56. Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007;69:1095-1101.
57. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
58. Hernandez DJ, Nielsen ME, Han M, Partin AW. Contemporary evaluation of the D'amico risk classifcation of prostate cancer. Urology. 2007;70:931-935.
59. Kattan M W, Wheeler TM, Scardino PT. Postoperative monogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17:1499-1507.
60. Graefen M, Karakiewicz PI, Cagiannos I, et al. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol. 2002;20: 951-956.
61. Stark JR, Perner S, Stampfer MJ, et al. Gleason score and lethal prostate cancer: Does 3 + 4 = 4 + 3? J Clin Oncol. 2009;27:3459-3464.
62. Navone NM, Labate ME, Troncoso P, et al. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site defne foci with metastatic potential. J Urol. 1999;161:304-308.
63. McDonnell TJ, Navone NM, Troncoso P, et al. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol. 1997;157: 569-574.
64. Sanchez P, Hernandez AM, Stecca B, et al. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci U S A. 2004;101:12561-12566.
65. Zunich SM, Douglas T, Valdovinos M, et al. Paracrine sonic hedgehog signalling by prostate cancer cells induces osteoblast differentiation. Mol Cancer. 2009;8:12.
66. Pound CR, Brawer MK, Partin AW. Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following defnitive therapy for clinically localized prostate cancer. Rev Urol. 2001;3:72-84.
67. Partin AW, Pearson JD, Landis PK, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 1994;43:649-659.
68. Patel A, Dorey F, Franklin J, deKernion JB. Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 1997;158:1441-1445.
69. Cannon GM Jr, Walsh PC, Partin AW, Pound CR. Prostate-specific antigen doubling time in the identifcation of patients at risk for progression after treatment and biochemical recurrence for prostate cancer. Urolog y. 2003;62 Suppl 1:2-8.
70. D'Amico AV, Moul J W, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376-1383.
71. Stewart AJ, Scher HI, Chen MH, et al. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol. 2005;23:6556-6560.
72. Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006;24:3984-3990.
73. Hussain M, Goldman B, Tangen C, et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol. 2009;27:2450-2456.
74. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467.
75. Petrylak D P, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006;98:516-521.
76. Shaul P W, Anderson RG. Role of plasmalemmal caveolae in signal transduction. Am J Physiol. 1998;275:L843-L851.
77. Sternberg P W, Schmid SL. Caveolin, cholesterol and Ras signalling. Nat Cell Biol. 1999;1:E35-E37.
78. Anderson RG, Jacobson K. A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science. 2002;296: 1821-1825.
79. Carver LA, Schnitzer JE, Anderson RG, Mohla S. Role of caveolae and lipid rafts in cancer: Workshop summary and future needs. Cancer Res. 2003;63:6571-6574.
80. Li S, Couet J, Lisanti M P. Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem. 1996;271:29182-29190.
81. Shatz M, Liscovitch M. Caveolin-1: A tumor-promoting role in human cancer. Int J Radiat Biol. 2008;84:177-189.
82. Glenney JR Jr. Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. J Biol Chem. 1989;264:20163-20166.
83. Razani B, Schlegel A, Liu J, Lisanti M P. Caveolin-1, a putative tumour suppressor gene. Biochem Soc Trans. 2001;29:494-499.
84. Williams TM, Lisanti M P. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol. 2005;288: C494-C506.
85. Rajjayabun PH, Garg S, Durkan GC, Charlton R, Robinson MC, Mellon JK. Caveolin-1 expression is associated with high-grade bladder cancer. Urolog y. 2001;58:811-814.
86. Kato K, Hida Y, Miyamoto M, et al. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer. 2002;94:929-933.
87. Yang G, Truong LD, Timme TL, et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res. 1998;4:1873-1880.
88. Yang G, Truong LD, Wheeler TM, Thompson TC. Caveolin-1 expression in clinically confined human prostate cancer: A novel prognostic marker. Cancer Res. 1999;59:5719-5723.
89. Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF. Caveolin-1 over expression is associated with aggressive prostate cancer recurrence. Prostate. 2007;67:614-622.
90. Li L, Ren CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol. 2003;23: 9389-9404.
91. Nasu Y, Timme TL, Yang G, et al. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med. 1998;4:1062-1064.
92. Li L, Yang G, Ebara S, et al. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res. 2001;61:4386-4392.
93. Tahir SA, Yang G, Ebara S, et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res. 2001;61:3882-3885.
94. Engelman JA, Zhang XL, Lisanti M P. Genes encoding human caveo-lin-1 and-2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett. 1998;436:403-410.
95. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol. 1998;153:141-148.
96. Cui J, Rohr LR, Swanson G, Speights VO, Maxwell T, Brothman AR. Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate. 2001;46:249-256.
97. Bachmann N, Haeusler J, Luedeke M, et al. Expression changes of CAV1 and EZH2, located on 7q31 approximately q36, are rarely related to genomic alterations in primary prostate carcinoma. Cancer Genet Cytogenet. 2008;182:103-110.
98. Gandellini P, Folini M, Longoni N, et al. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res. 2009;69:2287-2295.
99. Xin L, Teitell MA, Lawson DA, Kwon A, Mellinghoff IK, Witte ON. Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci U S A. 2006;103:7789-7794.
100. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A. 1999;96: 4240-4245.
101. Li L, Ren C, Yang G, Goltsov AA, Tabata K, Thompson TC. Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells. Mol Cancer Res. 2009;7:1781-1791.
102. Tahir SA, Park S, Thompson TC. Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells. Cancer Biol Ther. 2009;8.
103. Schlegel A, Arvan P, Lisanti M P. Caveolin-1 binding to endoplasmic reticulum membranes and entry into the regulated secretory pathway are regulated by serine phosphorylation. Protein sorting at the level of the endoplasmic reticulum. J Biol Chem. 2001;276: 4398-4408.
104. Llorente A, de Marco MC, Alonso MA. Caveolin-1 and MAL are located on prostasomes secreted by the prostate cancer PC-3 cell line. J Cell Sci. 2004;117:5343-5351.
105. Lu Q, Zhang J, Allison R, et al. Identification of extracellular delta-catenin accumulation for prostate cancer detection. Prostate. 2009;69:411-418.
106. Woodman SE, Ashton AW, Schubert W, et al. Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli. Am J Pathol. 2003;162:2059-2068.
107. Yang G, Addai J, Wheeler TM, et al. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum Pathol. 2007;38:1688-1695.
108. Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, Novario R. Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis. 2002;5:123-127.
109. Tahir SA, Frolov A, Hayes TG, et al. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res. 2006;12:4872-4875.